QQQ   308.42 (+2.49%)
AAPL   148.76 (+2.29%)
MSFT   258.24 (+2.17%)
META   184.84 (+20.72%)
GOOGL   106.71 (+6.25%)
AMZN   110.17 (+4.77%)
TSLA   189.48 (+4.45%)
NVDA   213.73 (+2.05%)
NIO   12.03 (-0.58%)
BABA   109.29 (-3.13%)
AMD   87.04 (+2.84%)
T   20.25 (+0.35%)
MU   62.72 (+0.19%)
F   14.18 (+2.83%)
CGC   3.13 (+1.62%)
GE   82.35 (+0.04%)
DIS   110.60 (+1.11%)
AMC   6.16 (+7.88%)
PFE   43.70 (-0.61%)
PYPL   86.27 (+4.05%)
NFLX   364.52 (+0.70%)
QQQ   308.42 (+2.49%)
AAPL   148.76 (+2.29%)
MSFT   258.24 (+2.17%)
META   184.84 (+20.72%)
GOOGL   106.71 (+6.25%)
AMZN   110.17 (+4.77%)
TSLA   189.48 (+4.45%)
NVDA   213.73 (+2.05%)
NIO   12.03 (-0.58%)
BABA   109.29 (-3.13%)
AMD   87.04 (+2.84%)
T   20.25 (+0.35%)
MU   62.72 (+0.19%)
F   14.18 (+2.83%)
CGC   3.13 (+1.62%)
GE   82.35 (+0.04%)
DIS   110.60 (+1.11%)
AMC   6.16 (+7.88%)
PFE   43.70 (-0.61%)
PYPL   86.27 (+4.05%)
NFLX   364.52 (+0.70%)
QQQ   308.42 (+2.49%)
AAPL   148.76 (+2.29%)
MSFT   258.24 (+2.17%)
META   184.84 (+20.72%)
GOOGL   106.71 (+6.25%)
AMZN   110.17 (+4.77%)
TSLA   189.48 (+4.45%)
NVDA   213.73 (+2.05%)
NIO   12.03 (-0.58%)
BABA   109.29 (-3.13%)
AMD   87.04 (+2.84%)
T   20.25 (+0.35%)
MU   62.72 (+0.19%)
F   14.18 (+2.83%)
CGC   3.13 (+1.62%)
GE   82.35 (+0.04%)
DIS   110.60 (+1.11%)
AMC   6.16 (+7.88%)
PFE   43.70 (-0.61%)
PYPL   86.27 (+4.05%)
NFLX   364.52 (+0.70%)
QQQ   308.42 (+2.49%)
AAPL   148.76 (+2.29%)
MSFT   258.24 (+2.17%)
META   184.84 (+20.72%)
GOOGL   106.71 (+6.25%)
AMZN   110.17 (+4.77%)
TSLA   189.48 (+4.45%)
NVDA   213.73 (+2.05%)
NIO   12.03 (-0.58%)
BABA   109.29 (-3.13%)
AMD   87.04 (+2.84%)
T   20.25 (+0.35%)
MU   62.72 (+0.19%)
F   14.18 (+2.83%)
CGC   3.13 (+1.62%)
GE   82.35 (+0.04%)
DIS   110.60 (+1.11%)
AMC   6.16 (+7.88%)
PFE   43.70 (-0.61%)
PYPL   86.27 (+4.05%)
NFLX   364.52 (+0.70%)
NASDAQ:INSM

Insmed - INSM Stock Forecast, Price & News

$21.79
+0.17 (+0.79%)
(As of 02/2/2023 10:34 AM ET)
Add
Compare
Today's Range
$21.74
$22.09
50-Day Range
$17.79
$21.69
52-Week Range
$16.41
$28.94
Volume
60,566 shs
Average Volume
1.39 million shs
Market Capitalization
$2.95 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.36

Insmed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.6% Upside
$43.36 Price Target
Short Interest
Bearish
7.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$875,661 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.66) to ($3.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

442nd out of 1,030 stocks

Pharmaceutical Preparations Industry

222nd out of 502 stocks


INSM stock logo

About Insmed (NASDAQ:INSM) Stock

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Stock News Headlines

Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Analyst Ratings for Insmed
Insmed To Present at the Nasdaq 47th Investor Conference
Insmed Director Trades Company's Stock
Insmed To Present at Three November Conferences
Why Insmed's Shares Fell 14.7% on Wednesday
Form 8-K INSMED Inc For: Oct 19 - StreetInsider.com
See More Headlines
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Company Calendar

Last Earnings
10/28/2021
Today
2/02/2023
Next Earnings (Estimated)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.36
High Stock Price Forecast
$53.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+99.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-434,650,000.00
Net Margins
-179.37%
Pretax Margin
-178.86%

Debt

Sales & Book Value

Annual Sales
$188.46 million
Book Value
$3.47 per share

Miscellaneous

Free Float
129,204,000
Market Cap
$2.95 billion
Optionable
Optionable
Beta
1.56

Social Links


Key Executives

  • Mr. William H. Lewis J.D.Mr. William H. Lewis J.D. (Age 50)
    Pres, CEO & Chairman
  • Mr. Paolo Tombesi (Age 55)
    Chief Financial Officer
  • Ms. Christine A. Pellizzari J.D. (Age 51)
    Chief Legal Officer & Corp. Sec.
  • Mr. Roger  AdsettMr. Roger Adsett (Age 50)
    Chief Commercial Officer
  • Dr. Paul D. Streck (Age 55)
    Advisor













INSM Stock - Frequently Asked Questions

Should I buy or sell Insmed stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings
or view top-rated stocks.

What is Insmed's stock price forecast for 2023?

9 Wall Street analysts have issued 12 month price targets for Insmed's stock. Their INSM share price forecasts range from $28.00 to $53.00. On average, they predict the company's stock price to reach $43.36 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price.
View analysts price targets for INSM
or view top-rated stocks among Wall Street analysts.

How have INSM shares performed in 2023?

Insmed's stock was trading at $19.98 on January 1st, 2023. Since then, INSM shares have increased by 8.2% and is now trading at $21.62.
View the best growth stocks for 2023 here
.

When is Insmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our INSM earnings forecast
.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings data on Thursday, October, 28th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.13. The biopharmaceutical company earned $46.80 million during the quarter, compared to the consensus estimate of $49.23 million. Insmed had a negative net margin of 179.37% and a negative trailing twelve-month return on equity of 319.03%. The firm's revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.63) EPS.

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.77%), Peregrine Capital Management LLC (0.26%), Scout Investments Inc. (0.24%), Rice Hall James & Associates LLC (0.18%), Hennion & Walsh Asset Management Inc. (0.10%) and State of New Jersey Common Pension Fund D (0.09%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends
.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $21.62.

How much money does Insmed make?

Insmed (NASDAQ:INSM) has a market capitalization of $2.93 billion and generates $188.46 million in revenue each year. The biopharmaceutical company earns $-434,650,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis.

How many employees does Insmed have?

The company employs 373 workers across the globe.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.

This page (NASDAQ:INSM) was last updated on 2/2/2023 by MarketBeat.com Staff